Insilico Medicine (HKG: 3696), the clinical‑stage biotechnology company powered by AI‑driven drug discovery, announced that it has completed first‑in‑human (FIH) dosing for ISM9528, a potential first‑in‑class non‑opioid analgesic drug candidate.
Milestone Snapshot
| Item | Detail |
|---|---|
| Company | Insilico Medicine (HKG: 3696) |
| Candidate | ISM9528 – potential first‑in‑class non‑opioid analgesic, oral therapy |
| Milestone | First‑in‑human (FIH) dosing completed |
| Milestone Date | 17 Nov 2026 |
| Origin | Nominated as preclinical candidate (PCC) by Insilico’s Abu Dhabi team in July 2026 |
| Portfolio Position | 31st PCC since 2021; second PCC generated from the company’s UAE R&D efforts |
| Indication Focus | Acute postoperative pain and neuropathic pain (preclinical models) |
Drug Profile & Preclinical Evidence
- Molecule: ISM9528, positioned as a potential first‑in‑class non‑opioid analgesic — targeting the vast, underserved pain market with a mechanism intended to avoid opioid‑associated addiction, tolerance, and respiratory‑depression risks.
- Route of Administration: Developed as a potential oral therapy, aligning with the outpatient and post‑discharge settings that dominate analgesic use.
- Preclinical Efficacy: In validated models of acute postoperative pain and neuropathic pain, ISM9528 demonstrated superior efficacy compared to the standard of care.
- Speed to Clinic: The candidate advanced from PCC nomination (July 2026) to first‑in‑human dosing (November 2026) in roughly four months — a timeline emblematic of Insilico’s AI‑accelerated discovery‑to‑clinic workflow.
- Geographic Diversification: ISM9528 is the second asset generated from Insilico’s UAE R&D efforts, following the company’s establishment of its Abu Dhabi site, and the 31st PCC since 2021 across its portfolio.
Market Impact & Outlook
- Non‑Opioid Analgesia Landscape: Chronic and acute pain remain among the largest therapeutic markets in global medicine, yet few genuinely novel non‑opioid mechanisms have reached the clinic; a first‑in‑class oral candidate with superior preclinical efficacy addresses a critical unmet need amplified by the opioid crisis.
- AI‑Drug‑Discovery Validation: Reaching FIH dosing four months after PCC nomination reinforces Insilico’s thesis that generative‑AI‑driven discovery can compress early development timelines — a differentiator it has now demonstrated across 31 preclinical candidates since 2021.
- UAE Hub Momentum: As the second PCC to emerge from the Abu Dhabi team, ISM9528 strengthens the strategic case for Insilico’s Middle East expansion and the UAE’s ambition to become a regional biotech R&D hub.
- Undisclosed Elements: Trial design details, dosing cohorts, specific targets/mechanism, and timelines for subsequent development phases were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development of ISM9528, its potential as a first‑in‑class non‑opioid analgesic, and Insilico Medicine’s AI‑driven pipeline expansion. Actual results may differ materially due to risks inherent in early‑stage clinical development, including safety findings in first‑in‑human studies, preclinical‑to‑clinical translation uncertainty, regulatory requirements, and competitive dynamics in pain therapeutics.-Fineline Info & Tech
